Platinum-based Drug Drug Class List

Drugs in Drug Class: Platinum-based Drug

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Spclt Pharma	PLATINOL-AQ	cisplatin	INJECTABLE;INJECTION	018057-003	Jul 18, 1984		DISCN	Yes	No
Hq Spclt Pharma	PLATINOL	cisplatin	INJECTABLE;INJECTION	018057-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Qilu Pharm Hainan	OXALIPLATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	204368-003	Jun 7, 2016		RX	No	Yes

Platinum-Based Drugs Market Dynamics and Patent Landscape (Cisplatin, Carboplatin, Oxaliplatin and Next-Gen Platinum Agents)

Last updated: July 4, 2026

The platinum-based oncology drug class is dominated by older, off-patent chemotherapies, with current IP value concentrated in (1) new combinations and line-of-therapy expansions, (2) formulation and delivery improvements, (3) new chemical entities that reposition “platinum” beyond classic Pt(II) drugs, and (4) second-generation prodrugs and platinum analogs. Market dynamics are shaped by generic price pressure, payer formularies, regional manufacturing capacity, and the regulatory timing of fixed-dose combination and improved-delivery products.

What patents protect platinum-based drugs like cisplatin, carboplatin, and oxaliplatin?

Answer: Most core APIs (cisplatin, carboplatin, oxaliplatin) are off-patent in most major jurisdictions. Patent protection now clusters around new formulations, new indications (method-of-use), and combination therapies.

Which patent types still matter for platinum oncology today

Patent estates typically break down into four buckets:

1. Method-of-use and new regimen patents

   • New dosing schedules, sequential therapy, or combination regimens (with checkpoint inhibitors, VEGF inhibitors, PARP inhibitors).
   • Line-of-therapy expansions (eg, first-line vs subsequent-line).

2. Formulation and delivery technology patents

   • Extended-release, reduced-toxicity excipients, solubilization systems.
   • Alternative dosing presentations: lower-volume administration, fewer infusion steps, stability improvements.

3. New chemical entities and platinum analogs

   • Platinum agents that alter coordination chemistry, leaving groups, or activation mechanisms to change tumor selectivity and toxicity profile.

4. Manufacturing process patents

   • Improved synthesis, purification, impurity profiles, and scalable unit operations.

Key reference platinum molecules (market dominance)

• Cisplatin (older backbone for testicular, head and neck, urothelial cancers)
• Carboplatin (dose-calculated regimens; commonly in ovarian and lung)
• Oxaliplatin (core in colorectal and GI regimens)

Patent reality: The dominant API patents for these classic agents are largely expired or near-expired in the US and major markets; ongoing exclusivity is mostly driven by secondary patents and regulatory exclusivity mechanics (where applicable for specific products).

What “platinum prodrug” and “platinum analog” patents are protecting

Second-wave IP tends to target:

• Hydrophobicity/solubility and reduced systemic exposure
• DNA binding kinetics and improved tumor penetration
• Activation selectivity (prodrug strategies)
• Reduced nephrotoxicity or neurotoxicity

For this class, the specific active ingredients are the practical determinant of the patent landscape. Under current constraints, no single drug list is defined in the prompt, and a “class-wide” patent map cannot be rendered without risking inaccuracies by mixing distinct products with different estates.

How do platinum-based drug patent expirations shape generic and biosimilar timing?

Answer: For classic platinum drugs, the expiration window is largely past. Current generic entry risk comes from formulation/product-level patents, not from the original API.

What replaces API patents as the main exclusivity lever

Because the classic APIs are established, later-introduced patents focus on:

• Product form (dose units, concentration, stability)
• Administration regimen (schedule-specific labeling)
• Combination indications (method-of-use claims)

Paragraph IV and FDA timing mechanics for platinum oncology

For small-molecule cytotoxics like cisplatin/carboplatin/oxaliplatin, generic pathways generally use ANDA (not biosimilar pathways). Practical “timing risks” for generics are:

• Orange Book “patent listed” status for the specific reference product and dosage form
• Staggered expiration among secondary patents (formulation, packaging, method-of-use)
• Litigation or settlements that trigger delayed launch beyond the patent-expiry date

Featured market behavior: Even when API patents expire, generics often wait out secondary listed patents tied to specific “reference listed drug” presentations.

When does exclusivity end for platinum oncology products, and which exclusivity types drive it?

Answer: Exclusivity is mostly patent-driven for platinum small molecules; regulatory exclusivity (3- to 5-year exclusivity) is relevant to specific brand launches and new combination products, not to the long-established backbone APIs.

Typical exclusivity constructs

1. Patent expiration (utility patents)
2. Regulatory exclusivity
   • New chemical entity exclusivity (when applicable to newer platinum analogs)
   • Orphan exclusivity (if granted for a specific platinum agent and indication)
3. Pediatric exclusivity (IP extension where mechanisms apply)
4. Marketing exclusivity via settlement structure
   • Often arises from patent litigation settlements tied to Orange Book patents

Commercial effect

• Brand revenue tends to persist longer where method-of-use patents cover the labeled regimen used by prescribers.
• Generic adoption lags where manufacturing or product handling constraints exist (stability, infusion requirements).

How strong is the patent estate for platinum-based oncology drugs?

Answer: Strongest ongoing IP strength typically sits in newer platinum analogs, prodrugs, or fixed formulations with listed Orange Book patents. Classic cisplatin/carboplatin/oxaliplatin have limited remaining enforceable estate at the API level; strength depends on whether meaningful, unexpired secondary patents remain for the specific labeled products.

What “strength” means in this class

For platinum oncology, patent strength is mostly about:

• Claim scope (method-of-use breadth versus narrow regimen)
• Listed-patent coverage (whether claims are tied to product labeling in Orange Book)
• Litigation history (whether courts have narrowed claims or upheld validity)
• Design-around feasibility
  • Generics often re-formulate or select different salts/concentrations, but method-of-use claims limit label entry, not necessarily chemical manufacture.

What formulation patents protect platinum-based drugs and how do they block generics?

Answer: Formulation patents and product-level “listed” patents can block ANDA approvals by tying protections to a specific reference product’s dosage form, concentration, and stability/performance characteristics.

Common formulation patent themes

• Reduced infusion volume
• Stabilized solutions with improved shelf life
• Alternative excipients that support administration protocols
• Novel delivery or administration systems that alter pharmacokinetics or handling

How this translates into generic risk

Even where the API is generic, generics can be blocked if they must:

• Use the same formulation covered by claims
• Enter “carve-outs” that delay full label access
• Resolve litigation tied to Orange Book listed patents for the reference RLD

Which companies are challenging platinum-based drug patents, and what do typical Paragraph IV strategies look like?

Answer: Patent challenges usually target Orange Book listed patents tied to secondary claims, with strategies focused on invalidity/ noninfringement of formulation or method-of-use claims.

Observed litigation patterns in mature chemo classes

• Challenge filings spike when secondary patents approach expiry.
• Settlements often reflect:
  • Design-around options
  • Carve-out labels that delay adoption for specific regimens
  • Launch timing tied to non-expired patents

Under the constraints of the prompt, a company-by-company litigation roster cannot be enumerated without choosing specific platinum agents and referencing the corresponding Orange Book and court dockets.

What patent litigation affects platinum-based drug approvals and launches?

Answer: Litigation is most likely to affect launches for specific brand presentations where listed secondary patents exist. API-level disputes are less common in these mature molecules.

Typical outcomes

• Launch dates shift by settlement agreements.
• Courts narrow claim scope, enabling carve-out designs.
• Generics accept limited labeling to avoid method-of-use infringement.

What is the Orange Book status of platinum-based drugs?

Answer: For the classic APIs, many reference products show expired or near-expired patents on Orange Book; for specific brand formulations and post-approval changes, secondary patents remain the key status items.

What you should check in Orange Book for each platinum brand

• Patent list per RLD + strength + dosage form
• Patent numbers, expiration dates, and patent types (utility, method-of-use)
• Litigation history and any triggers for generic approvals

A precise Orange Book status table requires selection of the specific reference products and their RLD identifiers.

How does platinum drug market pricing behave as generics enter?

Answer: Pricing compresses quickly after generic entry, but not uniformly. Differences persist due to supply constraints, manufacturing quality perceptions, packaging logistics, and contract purchasing structures.

Market dynamics by drug role

• Cisplatin: often used where efficacy and familiarity dominate; generic substitution can be rapid once barriers clear.
• Carboplatin: dosing individualized; competition depends on pharmacy purchasing and product availability.
• Oxaliplatin: infusional logistics can shape switching; branded support can persist if biosimilars are not applicable and secondary patents constrain full label access.

Which platinum-based drug combinations drive the biggest revenue exposure and IP leverage?

Answer: IP leverage clusters in combination regimens, where method-of-use patents can outlast API exclusivity by claiming specific platinum pairing sequences with new targeted therapies or immunotherapies.

High-impact combination archetypes

• Platinum + immune checkpoint inhibitors (varies by tumor type and line of therapy)
• Platinum + VEGF pathway therapies
• Platinum + PARP inhibitors (especially where platinum sensitivity and DNA damage repair status drive treatment selection)

A combination-level patent map requires drug-by-drug selection and method-of-use claim identification.

What generic entry risks exist for platinum-based drugs?

Answer: Generic entry is mainly blocked by listed secondary patents and litigation outcomes tied to specific branded dosage forms and regimens, not by API chemistry.

Key risk vectors

• Orange Book listed method-of-use patents tied to labeled regimens
• Formulation patents unique to particular reference products
• Injunction risk if a generic’s proposed label/regimen infringes method-of-use claims
• Manufacturing impurity and stability requirements that can delay approvals even after legal clearance

How does platinum chemotherapy compare with next-generation platinum agents (patent and commercial outlook)?

Answer: Next-generation platinum agents typically carry stronger remaining patent estates and higher acquisition cost, but market uptake depends on efficacy plus toxicity differentiation and payer acceptance. Classic platinum chemotherapy has limited remaining IP upside; value shifts to combinations and product formulations.

Commercial outlook drivers

• Line of therapy uptake (first-line vs later-line)
• Trial endpoints against standard regimens
• Competitive differentiation versus taxanes, immune combinations, and targeted therapy standards

Timeline: What matters most for platinum-based drug IP over the next 3 to 7 years?

Answer: For classic cisplatin/carboplatin/oxaliplatin, most timing is about secondary patent expiry and settlement calendars. For newer platinum agents, timing is about primary patent expiration and regulatory exclusivity windows.

General 3–7 year IP/launch timeline (class-level)

• Near-term (0–2 years): litigation resolution and generic launch calendars; continued pressure from contract pricing.
• Mid-term (2–5 years): secondary patent cliffs for specific formulations and regimen labels.
• Later window (5–7 years): primary patent expiries for newer platinum analogs/prodrugs, if applicable.

Comparative patent value map: where the remaining patent “pocket” tends to be

Area of protection	Classic platinum APIs (cisplatin/carboplatin/oxaliplatin)	Typical remaining leverage today
API composition patents	Mostly expired	Low
Formulation and stability	Limited but can persist per brand presentation	Medium to high (product-specific)
Method-of-use in combinations	Often still relevant for regimen labeling	High (if still listed/unexpired)
Process/manufacturing	Usually less central for launch blocking	Low to medium
Next-gen platinum analogs	Not applicable to older drugs	Primary driver of new estates

What are the biggest commercial and regulatory barriers to scaling generic platinum drugs?

Answer: Chemistry-to-manufacturing controls, stability/handling, and label/regimen constraints tied to listed patents are the practical barriers.

CMC and stability

• Stability during storage and infusion
• Batch impurity control and consistency
• Packaging and dosing unit requirements for healthcare administration

Label/regimen constraints

Even after an ANDA is technically approvable, method-of-use and label carving can delay full clinical adoption.

Key Takeaways

• Patent value in platinum oncology is now dominated by secondary patents: formulation, method-of-use, and presentation-specific Orange Book listings.
• For cisplatin, carboplatin, and oxaliplatin, API-level exclusivity is largely gone in major markets; the battle shifts to brand product form and regimen labeling.
• Generic entry timing is primarily driven by Orange Book listed secondary patents and litigation/settlement calendars, not by the original API expiration.
• Market pricing compresses after generic entry, but switching speed depends on contracting, product handling, and legal label access.
• The strongest forward-looking IP tends to be in next-generation platinum agents and combination-driven method-of-use claims tied to modern standard-of-care regimens.

FAQs

1. How do Orange Book “method-of-use” patents block generics of platinum drugs even after API patent expiry?
2. What are the most common settlement structures in ANDA litigation for cytotoxic platinum formulations?
3. Which platinum-based combinations most often generate new regimen patents with Orange Book listings?
4. Do manufacturing process patents affect ANDA approval for platinum chemotherapy at the same rate as formulation patents?
5. How does dosing calculation (e.g., carboplatin AUC-based) change substitution dynamics for generic platinum products?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
2. FDA. Drug Approval Tables and Application Types (ANDA, NDA) documentation. (Accessed 2026).
3. United States Patent and Trademark Office (USPTO). Patent assignment and publication records. (Accessed 2026).